Logo image of KYMR

KYMERA THERAPEUTICS INC (KYMR) Stock Price, Quote, News and Overview

NASDAQ:KYMR - Nasdaq - US5015751044 - Common Stock - Currency: USD

47.3  +4.17 (+9.67%)

KYMR Quote, Performance and Key Statistics

KYMERA THERAPEUTICS INC

NASDAQ:KYMR (6/3/2025, 9:40:10 AM)

47.3

+4.17 (+9.67%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High53.27
52 Week Low19.44
Market Cap3.08B
Shares65.12M
Float63.08M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-05 2025-08-05/bmo
IPO08-21 2020-08-21


KYMR short term performance overview.The bars show the price performance of KYMR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40

KYMR long term performance overview.The bars show the price performance of KYMR in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of KYMR is 47.3 USD. In the past month the price increased by 22.25%. In the past year, price increased by 30.86%.

KYMERA THERAPEUTICS INC / KYMR Daily stock chart

KYMR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.21 330.30B
AMGN AMGEN INC 13.86 154.66B
GILD GILEAD SCIENCES INC 14.1 135.72B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.10B
REGN REGENERON PHARMACEUTICALS 11.07 52.95B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.90B
ARGX ARGENX SE - ADR 100.04 35.12B
BNTX BIONTECH SE-ADR N/A 29.20B
ONC BEONE MEDICINES LTD-ADR 6.43 27.11B
NTRA NATERA INC N/A 21.90B
BIIB BIOGEN INC 8.27 19.16B
UTHR UNITED THERAPEUTICS CORP 12.94 14.62B

About KYMR

Company Profile

KYMR logo image Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company is headquartered in Watertown, Massachusetts and currently employs 188 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The firm's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. The company utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.

Company Info

KYMERA THERAPEUTICS INC

500 North Beacon Street, 4Th Floor

Watertown MASSACHUSETTS 02139 US

CEO: Nello Mainolfi

Employees: 188

KYMR Company Website

KYMR Investor Relations

Phone: 18572855314

KYMERA THERAPEUTICS INC / KYMR FAQ

What is the stock price of KYMERA THERAPEUTICS INC today?

The current stock price of KYMR is 47.3 USD. The price increased by 9.67% in the last trading session.


What is the ticker symbol for KYMERA THERAPEUTICS INC stock?

The exchange symbol of KYMERA THERAPEUTICS INC is KYMR and it is listed on the Nasdaq exchange.


On which exchange is KYMR stock listed?

KYMR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for KYMERA THERAPEUTICS INC stock?

25 analysts have analysed KYMR and the average price target is 59.5 USD. This implies a price increase of 25.79% is expected in the next year compared to the current price of 47.3. Check the KYMERA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is KYMERA THERAPEUTICS INC worth?

KYMERA THERAPEUTICS INC (KYMR) has a market capitalization of 3.08B USD. This makes KYMR a Mid Cap stock.


How many employees does KYMERA THERAPEUTICS INC have?

KYMERA THERAPEUTICS INC (KYMR) currently has 188 employees.


What are the support and resistance levels for KYMERA THERAPEUTICS INC (KYMR) stock?

KYMERA THERAPEUTICS INC (KYMR) has a support level at 29.4. Check the full technical report for a detailed analysis of KYMR support and resistance levels.


Is KYMERA THERAPEUTICS INC (KYMR) expected to grow?

The Revenue of KYMERA THERAPEUTICS INC (KYMR) is expected to grow by 19.88% in the next year. Check the estimates tab for more information on the KYMR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy KYMERA THERAPEUTICS INC (KYMR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does KYMERA THERAPEUTICS INC (KYMR) stock pay dividends?

KYMR does not pay a dividend.


When does KYMERA THERAPEUTICS INC (KYMR) report earnings?

KYMERA THERAPEUTICS INC (KYMR) will report earnings on 2025-08-05, before the market open.


What is the Price/Earnings (PE) ratio of KYMERA THERAPEUTICS INC (KYMR)?

KYMERA THERAPEUTICS INC (KYMR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.1).


What is the Short Interest ratio of KYMERA THERAPEUTICS INC (KYMR) stock?

The outstanding short interest for KYMERA THERAPEUTICS INC (KYMR) is 11.09% of its float. Check the ownership tab for more information on the KYMR short interest.


KYMR Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to KYMR. When comparing the yearly performance of all stocks, KYMR is one of the better performing stocks in the market, outperforming 91.36% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

KYMR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to KYMR. The financial health of KYMR is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KYMR Financial Highlights

Over the last trailing twelve months KYMR reported a non-GAAP Earnings per Share(EPS) of -3.1. The EPS decreased by -27.05% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -26.23%
ROE -30.64%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-32.26%
Sales Q2Q%114.83%
EPS 1Y (TTM)-27.05%
Revenue 1Y (TTM)-25.85%

KYMR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to KYMR. The Buy consensus is the average rating of analysts ratings from 25 analysts.

For the next year, analysts expect an EPS growth of -27.43% and a revenue growth 19.88% for KYMR


Ownership
Inst Owners111.32%
Ins Owners1.3%
Short Float %11.09%
Short Ratio8.25
Analysts
Analysts84.8
Price Target59.5 (25.79%)
EPS Next Y-27.43%
Revenue Next Year19.88%